2031 - 2040 of 8571 Results
Title
Year
-
RESTRICTEDTitle: The Role of Innate and Adaptive Immunity in Parkinson's DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: IOS PressVol: 3Issue #: 4Start Page: 493End Page: 514Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-130250Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd130250?id=journal-of-parkinsons-disease%2Fjpd130250Citation Count: 262
- Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable2014RESTRICTEDTitle: Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory RoundtableJournal Name: Journal of Parkinson's DiseasePublisher: IOS PressVol: 4Issue #: 4Start Page: 585End Page: 589Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-140385Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd140385?id=journal-of-parkinsons-disease%2Fjpd140385Citation Count: 16
-
RESTRICTEDTitle: Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the CriteriaJournal Name: Journal of Parkinson's DiseasePublisher: IOS PressVol: 4Issue #: 2Start Page: 131End Page: 137Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.3233/jpd-130304Best OA location URL: https://escholarship.org/content/qt1525m3ww/qt1525m3ww.pdf?t=rtgk9lCitation Count: 54
-
RESTRICTEDTitle: LRRK2: Cause, Risk, and MechanismJournal Name: Journal of Parkinson's DiseasePublisher: IOS PressVol: 3Issue #: 2Start Page: 85End Page: 103Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-130192Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd130192?id=journal-of-parkinsons-disease%2Fjpd130192Citation Count: 127
- Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?2021RESTRICTEDTitle: Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?Journal Name: Journal of Personalized MedicinePublisher: MDPI AGVol: 11Issue #: 9Start Page: 834End Page: 834Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3390/jpm11090834Best OA location URL: https://www.mdpi.com/2075-4426/11/9/834/pdf?version=1629944805Citation Count: 3
- BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED2019RESTRICTEDTitle: BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDREDJournal Name: The Journal Of Prevention of Alzheimer's DiseasePublisher: SERDIVol:Issue #:Start Page: 1End Page: 9Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.14283/jpad.2019.6Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925534Citation Count: 37
-
RESTRICTEDTitle: Malevolent lurkers no more: NMDA receptors come of ageJournal Name: The Journal of PhysiologyPublisher: WileyVol: 575Issue #: 2Start Page: 317End Page: 318Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1113/jphysiol.2006.114629Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1819446Citation Count: 6
-
RESTRICTEDTitle: Tardive Dyskinesia in Older Persons Taking AntipsychoticsJournal Name: Neuropsychiatric Disease and TreatmentPublisher: Informa UK LimitedVol: Volume 17Issue #:Start Page: 3127End Page: 3134Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.2147/ndt.s328301Best OA location URL: https://www.dovepress.com/getfile.php?fileID=74946Citation Count: 10
-
RESTRICTEDTitle: Levodopa-induced dyskinesia: a brief review of the ongoing clinical trialsJournal Name: Neurodegenerative Disease ManagementPublisher: Informa UK LimitedVol: 12Issue #: 2Start Page: 51End Page: 55Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.2217/nmt-2021-0051Citation Count: 3
- Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic2022RESTRICTEDTitle: Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinicJournal Name: Neurodegenerative Disease ManagementPublisher: Informa UK LimitedVol: 12Issue #: 4Start Page: 203End Page: 214Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.2217/nmt-2021-0055Citation Count: 7